Critical Analysis: SCYNEXIS (SCYX) & Akorn (AKRX)
SCYNEXIS (NASDAQ: SCYX) and Akorn (NASDAQ:AKRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Valuation & Earnings
This table compares SCYNEXIS and Akorn’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Akorn||$1.02 billion||4.07||$372.04 million||$0.99||33.55|
Akorn has higher revenue and earnings than SCYNEXIS.
This is a breakdown of current recommendations for SCYNEXIS and Akorn, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SCYNEXIS currently has a consensus price target of $11.00, suggesting a potential upside of 433.98%. Akorn has a consensus price target of $29.13, suggesting a potential downside of 12.30%. Given SCYNEXIS’s stronger consensus rating and higher probable upside, research analysts plainly believe SCYNEXIS is more favorable than Akorn.
Insider and Institutional Ownership
36.8% of SCYNEXIS shares are owned by institutional investors. Comparatively, 70.0% of Akorn shares are owned by institutional investors. 4.0% of SCYNEXIS shares are owned by insiders. Comparatively, 28.2% of Akorn shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares SCYNEXIS and Akorn’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
SCYNEXIS has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Akorn has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Akorn beats SCYNEXIS on 8 of the 12 factors compared between the two stocks.
SCYNEXIS Company Profile
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Akorn Company Profile
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.